Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB–IIB cervical carcinoma: A retrospective study of 288 patients†
Article first published online: 2 MAY 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 104, Issue 5, pages 480–485, 1 October 2011
How to Cite
Zheng, M., Huang, L., Liu, J.-H., Xiong, Y., Li, J.-D., Huang, X., He, L., Ren, Y.-F. and Wang, H.-Y. (2011), Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB–IIB cervical carcinoma: A retrospective study of 288 patients. J. Surg. Oncol., 104: 480–485. doi: 10.1002/jso.21956
Conflict of interest: None
- Issue published online: 6 SEP 2011
- Article first published online: 2 MAY 2011
- Manuscript Accepted: 31 MAR 2011
- Manuscript Received: 8 JAN 2011
- National Natural Science Foundation of China. Grant Number: 81072143
- Science and Technology Planning Project of Guangdong Province. Grant Number: 2009B030801018
- type II radical hysterectomy;
- cervical carcinoma;
- prognostic factors
Background and Objectives
The aim of this study was to evaluate type II radical hysterectomy with or without adjuvant therapy as a treatment for patients with pelvic lymph node metastasis (PLNM) and stage IB–IIB cervical carcinoma.
A total of 288 patients with stage IB–IIB cervical carcinoma and confirmed PLNM who underwent a type II radical hysterectomy between 1995 and 2005 were retrospectively evaluated.
The 5-year overall survival (OS) rate for this cohort was 65.6%, and independent prognostic factors identified for PLNM patients included a non-squamous cell histological subtype and parametrial involvement. Survival differences between patients that received or did not receive adjuvant treatment were also evaluated, and the 5-year OS and DFS rates for patients who did not receive adjuvant therapy (47 and 41.4%, respectively) were much lower than the rates for patients who did receive adjuvant therapies (67.7 and 59.4%, respectively). However, these differences were not statistically significant (OS, P = 0.057; DFS, P = 0.080).
Type II radical hysterectomy, in combination with adjuvant therapies, is an efficient treatment for PLNM patients with stage IB–IIB cervical cancer. J. Surg. Oncol. 2011; 104:480–485. © 2011 Wiley-Liss, Inc.